Fusion/entry inhibitors as therapies for HIV

Bibliography

• HERNANDEZ LD, HOFFMAN LR, WOLFSBERG TG et al.: Virus-cell and cell-cell fusion. Ann. Rev. Cell Dev. (1996) 12:627–661.
   PubMed Web of Science ®Google Scholar
• DENG H, LIU R, ELLMEIER W et al.:Identification of a major co-receptor for primary isolates of HIV-I. Nature (1996) 381 (6584):661–666. Description of CCR5 as a co-receptor for HIV.
   Google Scholar
• FENG Y, BRODER CC, KENNEDY PE et al.: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272(5263):872–877.
   PubMed Web of Science ®Google Scholar
• •• First description of an HIV co-receptor.
   Google Scholar
• BERSON JF, LONG D, DORANZ BJ et al.: A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus Type 1 strains. J. Viral. (1996) 70(9):6288–6295.
   PubMed Web of Science ®Google Scholar
• ALKHATIB G, COMBADIERE C, BRODER CC et al.: CC-CKR5: a RANTES, MIP-I alpha, MIP-Ibeta receptor as a fusion cofactor for macrophage-tropic HIV-I. Science (1996) 272(5270):1955–1958.
   Google Scholar
• •• Description of CCR5 as a co-receptor for HIV.
   Google Scholar
• DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381(6584):667–673.
   PubMed Web of Science ®Google Scholar
• •• Description of CCR5 as a co-receptor forHIV.
   Google Scholar
• CARR A, COOPER DA: Adverse effects of antiretroviral therapy. Lancet (2000) 356(9239):1423–1430.
   PubMed Web of Science ®Google Scholar
• Source IDdb © Current Drugs Ltd., London, UK.
   Google Scholar
• MAINO VC, SUNI MA, WORMSLEY SB et al.: Enhancement of HIV Type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV Type 1 infection receiving an HIV Type 1 immunogen. AIDS Res. Hum. Retroviruses (2000) 16(18):2065–2066.
   PubMed Web of Science ®Google Scholar
• LEBON F, LEDECQ M: Approaches to the design of effective HIV-1 protease inhibitors. Curr. Med. Chem. (2000) 7(4)455–477.
   PubMed Web of Science ®Google Scholar
• RANDO FR, NGUYEN-BAB N: Development of novel nucleoside analogues for use against drug resistant strains of HIV-1. Drug Disc. Today (2000) 5(10):465–476.
   PubMed Web of Science ®Google Scholar
• HOGBERG M, MORRISON I: HIV-1 non-nucleoside reverse transcriptase inhibitors. Expert Opin. Ther. Pat. (2000) 10(8):1189–1199.
   Web of Science ®Google Scholar
• DALE CJ, KENT SJ: Vaccines for HIV. Expert Opin. Ther. Pat. (2000) 10(8):1179–1188.
   Web of Science ®Google Scholar
• MADDON PJ, DALGLEISH AG, MCDOUGAL JS et al.: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 47(3):333–348.
   Google Scholar
• SMITH DH, BYRN RA, MARSTERS SA et al.: Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 238(4834):1704–1707.
   Google Scholar
• DAAR ES, HO DD: Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. Am. J. Med. (1991) 90(4A):225–265.
   Google Scholar
• GOMATOS PJ, STAMATOS NM, GENDELMAN HE et al.: Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells. J. immund. (1990) 144(10:4183–4188.
   PubMedGoogle Scholar
• MOORE JP, MCKEATING JA, HUANG YX et at.: Virions of primary human immunodeficiency virus Type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J ViroL (1992) 66(1):235–243.
   Google Scholar
• DAAR ES, LI XL, MOUDGIL T et al.: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus Type 1 isolates. Proc. Natl. Acad. Sci. USA (1990) 87(17):6574–6578.
   PubMed Web of Science ®Google Scholar
• RUSCONI S, MOONIS M, MERRILL DP et al.: Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus Type 1 activities. Antimicrob. Agents Chemother. (1996) 40(1):234–236.
   PubMed Web of Science ®Google Scholar
• VAN DAMME L, WRIGHT A, DEPRAETERE K et al.: A Phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Trans. Infic. (2000) 76(2):126–130.
   PubMed Web of Science ®Google Scholar
• TOSHIYUKI M, BOYD MR: Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob. Agents Chemother. (2001) 45(3):664–672.
   PubMed Web of Science ®Google Scholar
• ZHANG JL, CHOE H, DEZUBE BJ et al.:The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. Virology (1998) 244(2):530–541.
   PubMed Web of Science ®Google Scholar
• DEZUBE BJ, WONG TK, DAHL TA et al.: A fusion inhibitor (FP-21399) for the treatment of HIV infection: a Phase I study. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1998). Abstract 650.
   Google Scholar
• ALLAWAY GP, DAVIS-BRUNO KL, BEAUDRY GA et al.: Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV Type 1 isolates. AIDS Res. Hum. Retroviruses (1995) 11(5):533–539.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, POMALES AB, YUAN H et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. j Viral (1995) 69(11):6609–6617.
   PubMed Web of Science ®Google Scholar
• GAUDUIN MC, ALLAWAY GP, OLSON WC et al: CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus Type 1 isolates. J. Viral. (1998) 72(4):3475–3478.
   Google Scholar
• JACOBSON JM, LOWY I, FLETCHER CV et al.: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) Type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. (2000) 182(0:326–329.
   PubMedGoogle Scholar
• KWONG PD, WYATT R, MAJEED S et al.: Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des. (2000) 8(12):1329–1339.
   Google Scholar
• BERGER EA, DOMS RW, FENYO EM et al.: A new classification for HIV-1. Nature (1998) 391(6664):240.
   PubMed Web of Science ®Google Scholar
• •New nomenclature linking viral tropism to co-receptor usage.
   Google Scholar
• DEAN M, CARRINGTON M, WINKLER C et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science (1996) 273(5283):1856–1862.
   PubMed Web of Science ®Google Scholar
• HUANG Y, PAXTON WA, WOLINSKY SM et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. (1996) 2(11):1240–1243.
   PubMed Web of Science ®Google Scholar
• LIU R, PAXTON WA, CHOE S et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 86(3):367–377.
   PubMed Web of Science ®Google Scholar
• SAMSON M, LIBERT F, DORANZ BJ et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 382(6593):722–725.
   Google Scholar
• ZIMMERMAN PA, BUCKLER-WHITE A, ALKHATIB G et al.: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk MoL Med. (1997) 3(1):23–36.
   Google Scholar
• COCCHI F, DEVICO AL, GARZINO-DEMO A et al.: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by •• CD8+ T cells. Science (1995) 270(5243):1811–1815.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, CLAPHAM PR, PICARD L et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276:276–279.
   PubMed Web of Science ®Google Scholar
• MOSIER DE, PICCHIO GR, GULIZIA RJ et al.: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus Type 1 infection in vivo or rapidly select for CXCR4-using variants./ Viral. (1999) 73(5):3544–3550.
   PubMed Web of Science ®Google Scholar
• MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215–1224.
   PubMed Web of Science ®Google Scholar
• OLSON WC, RABUT GE, NAGASHIMA KA et al.: Differential inhibition of human immunodeficiency virus Type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Viral. (1999) 73(5):4145–4155.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, KETAS TJ, NAGASHIMA KA et al.: Potent, broad-spectrum inhibition of human immunodeficiency virus Type 1 by the CCR5 monoclonal antibody PRO 140. J. Viral. (2001) 75(2):579–588.
   PubMed Web of Science ®Google Scholar
• BABA M, NISHIMURA O, KANZAKI N et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA (1999) 96(10):5698–5703.
   PubMed Web of Science ®Google Scholar
• ••First report of a 'small molecule' CCR5antagonist.
   Google Scholar
• BAROUDY BM: A small molecule antagonist of CCR5 that effectively inhibits HIV-1 potential as a novel antiretroviral agent. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2000):S17.
   Google Scholar
• REYES G: Development of CCR5 antagonists as a new class of anti-HIV therapeutic. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (2001):L11.
   Google Scholar
• DORN CP, FINKE PE, OATES B et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioarg. Med. Chem. Lett. (2001) 11(2):259–264.
   PubMed Web of Science ®Google Scholar
• FINKE PE, MEURER LC, OATES B et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-Aryl-1- [N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioarg. Med. Chem. Lett. (2001) 11(2):265–270.
   PubMed Web of Science ®Google Scholar
• TACHIBANA K, HIROTA S, IIZASA H et al.: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 393(6685):591–594.
   PubMed Web of Science ®Google Scholar
• ZOU YR., KOTTMANN AH, KURODA M et al.: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 393(6685):595–599.
   PubMed Web of Science ®Google Scholar
• NAGASAWA T, HIROTA S, TACHIBANA K et al.: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 382(6592):635–638.
   Google Scholar
• BLEUL CC, FARZAN M, CHOE H et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382(6594):829–833.
   PubMed Web of Science ®Google Scholar
• OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382(6594):833–835.
   PubMed Web of Science ®Google Scholar
• AMARA A, GALL SL, SCHWARTZ 0 et al.: HIV coreceptor downregulation as antiviral principle: SDF-lalpha- dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication./ Exp. Med. (1997) 186(1):139–146.
   PubMed Web of Science ®Google Scholar
• O'BRIEN WA, SUMNER-SMITH M, MAO SH et al.: Anti-human immunodeficiency virus Type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Viral. (1996) 70(5):2825–2831.
   PubMed Web of Science ®Google Scholar
• DORANZ BJ, GROVIT-FERBAS K, SHARRON MP et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptot J. Exp. Med. (1997) 186(8):1395–1400.
   PubMed Web of Science ®Google Scholar
• DORANZ BJ, FILION LG, DIAZ-MITOMA F et al.: Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res. Hum. Retroviruses (2001) 17(6):475–486.
   PubMed Web of Science ®Google Scholar
• •Cautionary note of the need to phenotype virus as entry criterion for patients in clinical trials.
   Google Scholar
• MURAKAMI T, ZHANG TY, KOYANAGI Y et al.: Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus Type 1 infection. J. Viral. (1999) 73(9):7489–96.
   PubMed Web of Science ®Google Scholar
• TAMAMURA H, XU Y, HATTORI T et al.: A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun (1998) 253(3):877–882.
   PubMed Web of Science ®Google Scholar
• SCHOLS D, ESTE JA, HENSON G et al.: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. (1997) 35(3):147–156.
   PubMed Web of Science ®Google Scholar
• DONZELLA GA, SCHOLS D, LIN SW et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptot Nat. Med. (1998) 4(1):72–77.
   PubMed Web of Science ®Google Scholar
• ••Confirmation of CXCR4 as the target ofthe antiviral bicyclams.
   Google Scholar
• DE CLERCQ E: Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mal. Pharmacol. (2000) 57(5):833–839.
   PubMed Web of Science ®Google Scholar
• HENDRIX CW, FLEXNER C, MACFARLAND RT et al.: Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. (2000) 44(6):1667–1673.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: CXCR4 and CCR5 chemokine receptor antagonists as anti-HIV agents, with special emphasis o the CXCR4 antagonist, AMD-3100. Curr. Opin. Anti-Infect. Invest. Drugs (2000) 2(3):226–236.
   Google Scholar
• MACFARLAND RT, YASUDA N, WITVROUW M et al.: An orally bioavailable CXCR4 antagonist for inhibition of HIV replication. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1845.
   Google Scholar
• STRIZKI J: Development of SCH-C, a small molecule antagonist of CCR5, as a novel therapeutic. Keystone Symposium: Chemokines and Chemokine Receptors. Taos, USA (2001).
   Google Scholar
• SCHOLS D, ESTE JA, CABRERA C et al.: T-cell-line-tropic human immunodeficiency virus Type 1 that is made resistant to stromal cell-derived factor lalpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Viral. (1998) 72(5):4032–4037.
   PubMed Web of Science ®Google Scholar
• ESTE JA, CABRERA C, BLANCO J et al.:Shift of clinical human immunodeficiency virus Type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.J Viral. (1999) 73(7):5577–5585.
   PubMed Web of Science ®Google Scholar
• PHILPOTT S, WEISER B, ANASTOS K et al.: Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin. Invest. (2001) 107(4):431–438.
   PubMed Web of Science ®Google Scholar
• WILD CT, SHUGARS DC, GREEN WELL TK et al.: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus Type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA (1994) 91(21):9770–9774.
   PubMed Web of Science ®Google Scholar
• ••Early description of T-20, the first HIVfusion inhibitor.
   Google Scholar
• RIMSKY LT, SHUGARS DC, MATTHEWS TJ: Determinants of human immunodeficiency virus Type 1 resistance to gp41-derived inhibitory peptides. J. Viral. (1998) 72(2):986–993.
   Google Scholar
• CHAN DC, FASS D, BERGER JM et al.:Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 89(2):263–273.
   Google Scholar
• CHAN DC, CHUTKOWSKI CT, KIM PS: Evidence that a prominent cavity in the coiled coil of HIV Type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA (1998) 95(26):15613–15617.
   PubMed Web of Science ®Google Scholar
• ECKERT DM, MALASHKEVICH VN, HONG LH et al.: Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell (1999) 99(1):103–115.
   PubMed Web of Science ®Google Scholar
• PILCHER CD, ERON JJ, JR., NGO L et al.: Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. AIDS (1999) 13(15):2171–2173.
   PubMed Web of Science ®Google Scholar
• KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. (1998) 4(11):1302–1307.
   PubMed Web of Science ®Google Scholar
• SISTA P, MELBY T, DHINGRA U et al.:The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades. 5th International Workshop on HIV Drug Resistance and Treatment Strategies. Scottsdale, Arizona, USA (2001). Abstract 2.
   Google Scholar
• ERON J, MERIGAN T, KILBY M et al: A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of membrane fusion. 8th Conference on Retro viruses and Opportunistic Infections. Chicago, USA (2001).
   Google Scholar
• HOLZ-SMITH SL, SUN IC, JIN L et al: Role of human immunodeficiency virus (HIV) Type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Anti microb. Agents Chemother. (2001) 45(1):60–66.
   PubMed Web of Science ®Google Scholar
• DEBNATH AK, RADIGAN L, JIANG S: Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus Type 1. J Med. Chem. (1999) 42(17):3203–3209.
   Google Scholar
• GOTOH K, KANBARA K, TAMAMURA H et al.: Effects of CXCR4 antagonists on R5 HIV infection and biological characterization of resistant strains to CXCR4 antagonist T134. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (2000).
   Google Scholar
• DE VREESE K, KOFLER-MONGOLD V, LEUTGEB C et al.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Viral. (1996) 70(2):689–696.
   PubMed Web of Science ®Google Scholar
• ARAKAKI R, TAMAMURA H, PREMANATHAN M et al.: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Viral. (1999) 73(2):1719–1723.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA KA, THOMPSON DA ROSENFIELD SI et al.: Human immunodeficiency virus Type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. (2001) 183(7):1121–1125.
   PubMed Web of Science ®Google Scholar
• TREMBLAY CL, KOLLMANN C, GIGUEL F et al.: In vitro synergy observed between the fusion inhibitor T-20 and a CCR5 inhibitor TAK-779. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (2000).
   Google Scholar
• TREMBLAY CL, KOLLMANN C, GIGUEL F et al.: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. j Acquir. Immune Defic. Syndr. (2000) 25(2):99–102.
   Google Scholar